Status:
COMPLETED
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Telik
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung can...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Histologically confirmed non-small cell lung cancer
- Stage IV or IIIB
- Measurable disease by RECIST
- ECOG performance status of 0-1
- Adequate liver and renal function
- Adequate bone marrow reserve
Exclusion
- History of bone marrow transplantation or stem cell support
- Pregnant or lactating women
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00077883
Start Date
February 1 2004
End Date
March 1 2007
Last Update
July 25 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ. of MD, Greenbaum Cancer Center
Baltimore, Maryland, United States, 21201
2
The Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203
3
Univ. of TX, MD Anderson Cancer Center
Houston, Texas, United States, 77030